A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Stopped The study was stopped due to low subject enrollment. No safety issue or other concern factored into this decision.

Conditions

• Myelodysplastic Syndromes
• Anemia

Interventions

• DRUG: Placebo
• DRUG: Epoetin alfa
• DRUG: Placebo
• DRUG: Epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

• [object Object]